George Fivgas, MD
Ophthalmology · Baton Rouge, LANPI 1790787448
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,121 of the $5,621 with a category attached, or 73.3%. 22 manufacturers reported payments, led by Bausch & Lomb, A Division Of Bausch Health US, LLC at 37.1% of the total. Reporting peaked in 2019 at $2,354 and has fallen 69.4% since, to $720 in 2025.
Across 144 payments — averaging $39.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb, A Division Of Bausch Health US, LLC$2K
- Alcon$870
- Regeneron Healthcare Solutions, Inc.$561
- Genentech USA, Inc.$534
- AbbVie$366
- Apellis Pharmaceuticals, Inc.$208
- plus $998 from 16 others
What the payments were for
- Consulting fees$1,50027%
- Food & beverage$4,12173%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 21 | $2,086 |
| Alcon | 7 | $870 |
| Regeneron Healthcare Solutions, Inc. | 24 | $561 |
| Genentech USA, Inc. | 24 | $534 |
| AbbVie(2 entities) | 21 | $366 |
| Apellis Pharmaceuticals, Inc. | 8 | $208 |
| Astellas Pharma US Inc | 7 | $190 |
| Biotissue Holdings Inc. | 1 | $164 |
| Kala Pharmaceuticals, Inc. | 4 | $97 |
| Aerie Pharmaceuticals, Inc. | 4 | $75 |
| Alimera Sciences, Inc. | 4 | $74 |
| Dompe US, Inc. | 2 | $66 |
| Novartis | 3 | $51 |
| Eyevance Pharmaceuticals LLC | 3 | $43 |
| Coherus Oncology, Inc. | 2 | $43 |
| Amgen | 1 | $41 |
| Biogen | 2 | $40 |
| Sun Pharmaceutical Industries Inc. | 2 | $40 |
| Bausch & Lomb Americas Inc. | 1 | $22 |
| Shire North American Group Inc | 1 | $21 |
| Oyster Point Pharma, Inc. | 1 | $17 |
| Harrow Eye, LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,621 in reported general payments places this provider in the 80th percentile of 286 ophthalmology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 518 | $19,492 |
| Lotemax SmLoteprednol Etabonate | 32 | $14,133 |
| ProlensaBromfenac Sodium | 19 | $7,206 |
| Ketorolac Tromethamine | 297 | $6,951 |
| IlevroNepafenac | 12 | $5,898 |
| Bromfenac Sodium | 12 | $3,332 |
| Loteprednol Etabonate | 24 | $3,186 |
| Alphagan PBrimonidine Tartrate | 13 | $2,946 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 14 | $2,915 |
| Brimonidine Tartrate | 55 | $2,673 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 156 | $2,610 |
| Fluorometholone | 31 | $2,436 |
| Atropine Sulfate | 38 | $1,398 |
| Dorzolamide Hcl | 78 | $1,287 |
| Ofloxacin | 105 | $1,277 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Prolensa, Loteprednol Etabonate | $2,086 | $24,52575 claims |
| NovartisIlevro | $51 | $5,89812 claims |
| AbbVieAlphagan P | $366 | $2,94613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 286 ophthalmology providers in Louisiana.
Other ophthalmology in Baton Rouge
- Blake WilliamsonBaton Rouge$443K
- Charles WilliamsonBaton Rouge$16K
- David FargasonBaton Rouge$6K
- Philip EhrlichBaton Rouge$6K
- Daniel NelsonBaton Rouge$6K
- Michael MorganBaton Rouge$6K
- Thomas StuckeyBaton Rouge$6K
- Devin TranBaton Rouge$5K
- Rebecca MetzingerNew Orleans$63K
- Ze ZhangNew Orleans$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.